ArticleHaematologica2022
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
Abstract read
In one paragraph
Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors.Blood research · 2025Article
- Drug-Induced Liver Injury Associated With Emerging Cancer Therapies.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments.World journal of gastroenterology · 2024Article
- Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors.World journal of gastroenterology · 2024Article
- Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents.Cancers · 2024Review
- Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis.World journal of gastroenterology · 2024Review
- Risk of Hepatitis B Reactivation in Patients Receiving Ibrutinib: The National Veterans Affairs Cohort.Open forum infectious diseases · 2024Article
- NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia.Annals of hematology · 2024Article
- Management of infections for patient treated with ibrutinib in clinical practice.Frontiers in oncology · 2024Review
- Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.World journal of gastroenterology · 2023Review
- Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.Virology journal · 2023Article
- Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors.Clinical lymphoma, myeloma & leukemia · 2023Article
- How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists.Current oncology (Toronto, Ont.) · 2023Article
- Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib.Cancer research and treatment · 2023Article
- Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Idanna InnocentiSezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma.
Gianluigi RedaU.O.C. Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.
Andrea VisentinDepartment of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova.
Marta CosciaDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino.
Marina MottaSC Ematologia, ASST Spedali Civili, Brescia.
Roberta MurruHematology and Stem Cell Transplantation Unit, Ospedale A. Businco, ARNAS "G.Brotzu", Cagliari.
Riccardo MoiaDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara.
Massimo GentileUOC Ematologia AO di Cosenza, Presidio Ospedaliero Annunziata, Cosenza.
Elsa PenneseU.O.S.D. Centro Diagnosi e Terapia dei Linfomi, Dipartimento Oncologico-Ematologico, Presidio Ospedaliero "Spirito Santo", Pescara.
Francesca Maria QuagliaDepartment of Medicine, Section of Hematology, University of Verona, Verona.
Francesco AlbanoDepartment of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari.
Ramona CassinU.O.C. Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.
Marina DeodatoASST Grande Ospedale Metropolitano Niguarda Hospital, Milano.
Claudia IeloHematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Roma.
Anna Maria FrustaciASST Grande Ospedale Metropolitano Niguarda Hospital, Milano.
Alfonso PiciocchiGIMEMA Foundation, Roma.
Arianna RughiniGIMEMA Foundation, Roma.
Valentina ArenaGIMEMA Foundation, Roma.
Daniela Di SevoGIMEMA Foundation, Roma.
Annamaria TomassoSezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma.
Francesco AutoreSezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma.
Giovanni Del PoetaUOC Unit of Hematology and Stem Cell Transplantation, AOU Policlinico Tor Vergata Roma, Roma.
Lydia ScarfòStrategic Research Program on CLL, Università Vita Salute and IRCSS Ospedale San Raffaele, Milano.
Francesca Romana MauroHematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Roma.
Alessandra TedeschiASST Grande Ospedale Metropolitano Niguarda Hospital, Milano.
Livio TrentinDepartment of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova.
Maurizio PompiliDipartimento di Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma.
Robin FoàHematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Roma.
Paolo GhiaStrategic Research Program on CLL, Università Vita Salute and IRCSS Ospedale San Raffaele, Milano.
Antonio CuneoHematology section, Department of Medical Sciences, University of Ferrara, Ferrara.
Luca LaurentiSezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma. luca.laurenti@unicatt.it.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hepatitis B, ChronicLeukemia, Lymphocytic, Chronic, B-CellAdenineAntiviral AgentsHepatitis B virusHumansPiperidinesRetrospective StudiesVirus ActivationAdenineAntiviral AgentsibrutinibPiperidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.